By Crystal Phend, Staff Writer, MedPage Today Reviewed by Zalman S. Agus, MD; Emeritus Professor at the University of Pennsylvania School of Medicine. September 04, 2007 While, overall, women with advanced stage lung cancer tend to live longer than men, the same is not true for premenopausal women, researchers found. Non-small-cell lung cancer survival was longest, at 11.6 months, for postmenopausal women, intermediate for men, and shortest, at 7.0 months, for premenopausal women younger than age 45 in pooled analysis of two large trials presented here at the International Association for the Study of Lung Cancer world conference. The female survival advantage appeared to be primarily accounted for by women over age 60, which supports the role of estrogen in lung cancer, reported Heather A. Wakelee, M.D., of Stanford (Calif.) University, and colleagues. "Consistently across stages, across studies, women live longer than men and here we have the younger women . . . doing worse than men," Dr. Wakelee said. "That's something that we really hadn't seen before." "One of the big things that's been coming out in lung cancer is the estrogen story," she said. "At least in the lab it's been shown that estrogen can stimulate lung cancer growth." So, the researchers looked to see if the differences in survival between women and men might be mediated by hormonal status as hypothesized in a prior observational study. They analyzed data for 1,590 non-small-cell lung cancer patients from two Eastern Cooperate Oncology Group (ECOG) trials, excluding those treated with bevacizumab (Avastin) in one of the trials because of confounding factors. There was no difference in prognostic factors across age and gender groups. The majority of participants were men (62%) and at least 60 years old (58.2%). Median survival was significantly shorter among women younger than age 60, which was chosen as a cut-off age for menopausal status, than among older women (9.0 months versus 11.6, P=0.029). For men, there was no significant difference between those younger than 60 or 60 and older (P=0.17). When the researchers further stratified by age to separate out women who were clearly premenopausal, the difference was even more dramatic and showed opposite trends for men and women. The median survival findings were: 7.0 months for women younger than 45, 9.5 months for women 45 to 59, 11.6 months for women 60 or older (P=0.05). 8.7 months for men younger than 45, 8.3 months for men 45 to 59, and 7.4 months for those 60 or older (P=0.022). A significant difference in survival between men and women only at age 60 or after (difference 1.7 months younger than 45, P=0.39; 1.2 months 45 to 59, P=0.059; 4.2 months 60 and older, P<0.0001). Likewise, women younger than 60 had significantly shorter progression-free survival than postmenopausal women (3.8 months versus 4.7, P=0.0095) whereas there was no difference among men (3.4 months versus 4.0, P=0.50). Although there are factors other than hormonal status that could have an impact on the difference in survival between younger and older women, future studies should analyze whether early induction of menopause with chemotherapy is beneficial, Dr. Wakelee said, as some studies have found for breast cancer. Primary source: International Association for the Study of Lung Cancer meeting Source reference: Wakelee HA, et al "Menopausal status of women may affect survival in advanced NSCLC: Analysis of recent Eastern Cooperate Oncology Group (ECOG) studies using age of 60 years or older as a surrogate marker" IASLC meeting 2007; P1-052. Remember we are NOT Doctors and have NO medical training. This site is like an Encylopedia - there are many pages, many links on many topics. Support our work with any size DONATION - see left side of any page - for how to donate. You can help raise awareness of CAM.